SLC45A2 PEPTIDES FOR IMMUNOTHERAPY

• 收藏
• 分享

专利权人:

THE UNIVERSITY OF TEXAS SYSTEM;BOARD OF REGENTS

发明人:

LIZEE, Gregory,YEE, Cassian,HWU, Patrick,ROSZIK, Janos

申请号：

SG11201804648R

公开号：

SG11201804648RA

申请日:

2016.12.02

申请国别(地区):

SG

年份:

2018

代理人:

摘要：

Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/